{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:25:30Z","timestamp":1773937530754,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970163"],"award-info":[{"award-number":["81970163"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272325"],"award-info":[{"award-number":["81272325"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700165"],"award-info":[{"award-number":["81700165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770193"],"award-info":[{"award-number":["81770193"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC1303403"],"award-info":[{"award-number":["2016YFC1303403"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>NK cells have important functions in resisting cytomegalovirus infection, as they proliferate after viral infection and have certain immunological memory. Here, we report infusion of haploid donor-derived natural killer cells to treat two pediatric patients with Wiskott-Aldrich syndrome (WAS) who were infected with cytomegalovirus after cord blood transplantation (CBT), which successfully cleared the viral infection in both patients.<\/jats:p>","DOI":"10.3389\/fmed.2022.988847","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T04:58:46Z","timestamp":1665377926000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Natural killer cell infusion for cytomegalovirus infection in pediatric patients with Wiskott-Aldrich syndrome following cord blood transplantation: A case report and literature review"],"prefix":"10.3389","volume":"9","author":[{"given":"Yongwei","family":"Yue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cellimm.2019.03.004","article-title":"Wiskott-Aldrich syndrome protein may be critical for CD8(+) T cell function following MCMV infection","volume":"338","author":"Li","year":"2019","journal-title":"Cell Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaci.2012.08.050","article-title":"Reduced type I interferon production by dendritic cells and weakened antiviral immunity in patients with Wiskott-Aldrich syndrome protein deficiency","volume":"131","author":"Lang","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/ajh.20780","article-title":"Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab","volume":"82","author":"Cheung","year":"2007","journal-title":"Am J Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/QCO.0000000000000375","article-title":"Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options","volume":"30","author":"Fuji","year":"2017","journal-title":"Curr Opin Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/17474086.2016.1174571","article-title":"Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Maffini","year":"2016","journal-title":"Expert Rev Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin Pharmacol Drug Dev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/jpids\/piz050","article-title":"Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient","volume":"9","author":"Kilgore","year":"2020","journal-title":"J Pediatric Infect Dis Soc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am J Transplant."},{"key":"B16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/TP.0b013e3181e94106","article-title":"Utility of leflunomide in the treatment of complex cytomegalovirus syndromes","volume":"90","author":"Avery","year":"2010","journal-title":"Transplantation."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.bbmt.2019.04.028","article-title":"Use of leflunomide for treatment of cytomegalovirus infection in recipients of allogeneic stem cell transplant","volume":"25","author":"Gokarn","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2004-05-2058","article-title":"Imprint of human cytomegalovirus infection on the NK cell receptor repertoire","volume":"104","author":"Gum\u00e1","year":"2004","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1172\/JCI77440","article-title":"IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion","volume":"124","author":"R\u00f6lle","year":"2014","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1038\/ncomms6639","article-title":"Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients","volume":"5","author":"Ali","year":"2014","journal-title":"Nat Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"eaat8116","DOI":"10.1126\/sciimmunol.aat8116","article-title":"Human natural killer cells mediate adaptive immunity to viral antigens","volume":"4","author":"Nikzad","year":"2019","journal-title":"Sci Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3389\/fcimb.2020.00208","article-title":"NK Cell-mediated recall responses: memory-like, adaptive, or antigen-specific?","volume":"10","author":"Stary","year":"2020","journal-title":"Front Cell Infect Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/bmt.2012.162","article-title":"Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers","volume":"48","author":"Stern","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"B24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.bbmt.2014.01.031","article-title":"Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study","volume":"20","author":"Choi","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol Blood Marrow Transplant."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.988847\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T04:58:50Z","timestamp":1665377930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.988847\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":26,"alternative-id":["10.3389\/fmed.2022.988847"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.988847","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"article-number":"988847"}}